MS Research Study Investigating a Novel Approach for an FDA-Approved Medication

This year-long study is testing the efficacy and safety in treating Relapsing-Remitting Multiple Sclerosis (RRMS) with the medication Glatiramer Acetate (Copaxone) injection when a 40 mg is administered three times a week (rather than an injection everyday) versus placebo.

Major Inclusion/Exclusion

• Ages 18-55
• Must have NEVER have taken Copaxone
• Must have a confirmed and documented MS diagnosis
• Use of cladribine within the last two years is excluded